Polycystic Ovarian Syndrome (PCOS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Polycystic Ovarian Syndrome (PCOS) Marketed and Pipeline Drugs Report Overview
Polycystic Ovarian Syndrome (PCOS) is a complex condition characterized by elevated androgen levels, menstrual irregularities, and/or small cysts on one or both ovaries. It stands as the most prevalent hormonal disorder affecting females of reproductive age. Genetic and environmental factors are responsible for the etiology of this condition. Unhealthy lifestyle choices, dietary habits, or exposure to infectious agents tend to increase the risk of developing PCOS.
Key Mechanisms of Action (Marketed) | · Receptor Agonist
· Enzyme Activator · Enzyme Inhibitor · Receptor Antagonist · Transport Inhibitor |
Key Routes of Administration (Marketed) | · Oral
· Injection |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
The Polycystic Ovarian Syndrome Marketed and Pipeline Drugs Market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, and pricing and reimbursement of therapy in major countries. Furthermore, the report analyzes late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for polycystic ovarian syndrome.
The report also provides actionable insights into the clinical and commercial landscapes of polycystic ovarian syndrome drugs, M&A deals, and market catalysts. These critical data will help you develop and design your in-licensing and out-licensing strategies. Furthermore, identify companies with the most robust pipelines to create smart business goals.
Key Mechanisms of Action (Pipeline) | · Receptor Agonist
· Receptor Antagonist · Enzyme Activator · Enzyme Inhibitor |
Key Molecule Types (Pipeline) | · Biologic
· Small Molecule · Oligonucleotide |
Key Routes of Administration (Pipeline) | · Injection
· Oral · Suppository · Topical |
Top Sponsors (Marketed and Pipeline Drugs) | · Arak University of Medical Sciences
· Tehran University of Medical Sciences · Tabriz University of Medical Sciences · Shahid Beheshti University of Medical Sciences · Iran University of Medical Sciences |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Polycystic Ovarian Syndrome Marketed Drugs Market Segmentation by Mechanisms of Action
The key MoA of the marketed drugs for polycystic ovarian syndrome include receptor agonist, receptor antagonist, enzyme activator, enzyme inhibitor, and transporter inhibitor among others. Most of the marketed drugs followed receptor agonist MoA in 2023 in the polycystic ovarian syndrome market.
Polycystic Ovarian Syndrome Marketed Drugs Market Analysis by Mechanisms of Action, 2023 (%)
Buy the Full Report for More MoA insights into the Polycystic Ovarian Syndrome Marketed Drugs
Polycystic Ovarian Syndrome Marketed Drugs Market Segmentation by Routes of Administration
The key RoA of polycystic ovarian syndrome marketed drugs include oral and injection. Most marketed drugs that were available for polycystic ovarian syndrome were oral therapies, followed by the injection therapies.
Polycystic Ovarian Syndrome Marketed Drugs Market Analysis by Routes of Administration, 2023 (%)
Buy the Full Report for More RoA insights into the Polycystic Ovarian Syndrome Marketed Drugs
Polycystic Ovarian Syndrome Pipeline Drugs Market Segmentation by Mechanisms of Action
The key MoA of the drugs in the polycystic ovarian syndrome pipeline mainly includes receptor agonists, receptor antagonists, enzyme inhibitor, and enzyme activators. Most of the pipeline drugs undergoing development for polycystic ovarian syndrome followed receptor agonist MoA in 2023.
Polycystic Ovarian Syndrome Pipeline Drugs Market Analysis by Mechanisms of Action, 2023 (%)
Buy the Full Report for More MoA Insights into the Polycystic Ovarian Syndrome Pipeline Drugs Market
Polycystic Ovarian Syndrome Pipeline Drugs Market Segmentation by Routes of Administration
The key RoA of the drugs in the polycystic ovarian syndrome pipeline mainly includes injection, oral, topical, and suppository. In 2023, most pipeline drugs that were under development for polycystic ovarian syndrome were oral formulations.
Polycystic Ovarian Syndrome Pipeline Drugs Market Analysis by Routes of Administration, 2023 (%)
Buy the Full Report for More RoA Insights into the Polycystic Ovarian Syndrome Pipeline Drugs Market
Polycystic Ovarian Syndrome Pipeline Drugs Market Segmentation by Molecule Types
The key molecule types of polycystic ovarian syndrome pipeline drugs are biologic, oligonucleotide, and small molecule. In 2023, the leading molecule type for polycystic ovarian syndrome pipeline drugs was small molecule.
Premature Labor Pipeline Drugs Market Analysis by Molecule Types, 2023 (%)
Buy the Full Report for More Molecule Type Insights into the Polycystic Ovarian Syndrome Pipeline Drugs Market
Polycystic Ovarian Syndrome Marketed and Pipeline Drugs Market – Competitive Landscape
A few of the top sponsors in the polycystic ovarian syndrome marketed and pipeline drugs market are:
- Arak University of Medical Sciences
- Tehran University of Medical Sciences
- Tabriz University of Medical Sciences
- Shahid Beheshti University of Medical Sciences
- Iran University of Medical Sciences
Arak University of Medical Sciences sponsored the highest number of trials in 2023.
Polycystic Ovarian Syndrome Marketed and Pipeline Drugs Market Analysis by Sponsors, 2023 (%)
Buy the Full Report for More Sponsor Insights into the Polycystic Ovarian Syndrome Marketed and Pipeline Drugs Market
Segments Covered in the Report
Polycystic Ovarian Syndrome Marketed Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Receptor Agonist
- Enzyme Activator
- Enzyme Inhibitor
- Receptor Antagonist
- Transport Inhibitor
Polycystic Ovarian Syndrome Marketed Drugs Routes of Administration Outlook (Number of Drugs, 2023)
- Oral
- Injection
Polycystic Ovarian Syndrome Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Receptor Agonist
- Receptor Antagonist
- Enzyme Activator
- Enzyme Inhibitor
Polycystic Ovarian Syndrome Pipeline Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Biologic
- Small Molecule
- Oligonucleotide
Polycystic Ovarian Syndrome Pipeline Drugs Routes of Administration Outlook (Number of Drugs, 2023)
- Injection
- Oral
- Suppository
- Topical
Scope
The key components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the PL market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PL market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which was the leading MoA for polycystic ovarian syndrome marketed drugs in 2023?
Most of the drugs followed receptor agonist MoA in 2023 in the polycystic ovarian syndrome drugs market.
-
Which was the leading RoA for polycystic ovarian syndrome marketed drugs in 2023?
In 2023, most marketed drugs that were available for polycystic ovarian syndrome were oral therapies.
-
Which was the leading molecule type for polycystic ovarian syndrome pipeline drugs in 2023?
In 2023, most of the drugs in development for polycystic ovarian syndrome were small molecules.
-
Who are the top sponsors in the polycystic ovarian syndrome marketed and pipeline drugs market?
A few of the top sponsors in the polycystic ovarian syndrome marketed and pipeline drugs market are Arak University of Medical Sciences, Tehran University of Medical Sciences, Tabriz University of Medical Sciences, Shahid Beheshti University of Medical Sciences, and Iran University of Medical Sciences among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.